TB-500 + Egrifta (Tesamorelin) Stack: Complete Protocol

What Is TB-500 and How Does It Work?

TB-500 is a synthetic 7-amino-acid peptide derived from the actin-sequestering domain of thymosin beta-4 (Tβ4), specifically residues 17-23 (Ac-LKKTETQ). The full native Tβ4 protein is a 43-amino-acid, 4.9 kDa polypeptide found in virtually every nucleated mammalian cell, with particularly high concentrations in platelets and wound fluid. Researchers isolated the biologically active segment to produce a shorter, more manufacturable compound that retains several of the parent molecule's tissue-repair properties.

Mechanism at the Cellular Level

Tβ4 and its active fragment regulate the G-actin / F-actin equilibrium inside cells. By sequestering G-actin monomers, TB-500 indirectly enables cell migration, a rate-limiting step in wound closure and angiogenesis. A 2010 paper in the Annals of the New York Academy of Sciences confirmed that Tβ4 promotes corneal epithelial migration in vivo and that the LKKTETQ fragment is sufficient to drive this effect [1].

Beyond actin dynamics, Tβ4 upregulates anti-apoptotic genes including Bcl-2 and downregulates inflammatory mediators such as NF-kB-driven cytokines. A rat myocardial infarction model demonstrated that systemic Tβ4 administration reduced infarct size by roughly 30% and improved fractional shortening at 28 days compared with saline controls [2]. That datum is rodent-only, and no equivalent human cardiac RCT exists.

Pharmacokinetics

TB-500 is typically administered subcutaneously. Half-life data in humans are sparse; animal studies suggest the active fragment is cleared within 2-4 hours, but tissue-level effects on gene expression persist considerably longer. Practitioners therefore use twice-weekly rather than daily dosing to match the downstream biological window rather than peak plasma concentration.

What Is Egrifta (Tesamorelin) and How Does It Work?

Tesamorelin is a synthetic analogue of endogenous growth-hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid GHRH sequence stabilized with a trans-3-hexenoic acid group at the N-terminus. The FDA approved Egrifta (the original 1 mg/vial formulation) in November 2010 and the higher-concentration Egrifta SV (2 mg/vial) in 2019, both specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy [3].

IGF-1 and the GH Axis

Tesamorelin binds pituitary GHRH receptors, stimulating natural, pulsatile GH release rather than flooding the system with exogenous GH. The liver then converts GH pulses into circulating IGF-1. In the key Phase 3 trials (N=816 across two studies), tesamorelin 2 mg/day subcutaneously reduced visceral adipose tissue (VAT) by a mean of 15.2% versus 5.0% for placebo at 26 weeks (P<0.001), with IGF-1 rising by approximately 114 mcg/L from baseline [4].

Why Pulsatility Matters

Continuous supraphysiologic GH exposure (as with recombinant HGH injections) suppresses the GH axis through somatostatin feedback and increases the risk of adverse metabolic effects including insulin resistance. Because tesamorelin works through the pituitary's own secretory machinery, it preserves normal GH pulsatility, which appears to confer a more favorable glucose tolerance profile than exogenous GH. A 52-week extension analysis found no statistically significant worsening of fasting glucose or HbA1c compared with placebo in the HIV-lipodystrophy population [5].

Rationale for Combining TB-500 with Tesamorelin

Distinct Receptor Pathways

No evidence suggests that TB-500 and tesamorelin compete for the same receptor or share a downstream signaling pathway in a way that would cause antagonism. TB-500 acts primarily on actin cytoskeleton dynamics, VEGF-mediated angiogenesis, and inflammatory gene regulation [1]. Tesamorelin acts on pituitary GHRH receptors to raise systemic IGF-1 [4]. These two mechanisms are additive in theory: TB-500 accelerates local tissue repair while tesamorelin raises the systemic anabolic environment through IGF-1.

Where the Combination Might Have Clinical Logic

IGF-1 is itself a tissue-repair promoter. A 2017 review in the Journal of Cachexia, Sarcopenia and Muscle noted that IGF-1 stimulates satellite cell proliferation and collagen synthesis in skeletal muscle, effects that are conceptually complementary to TB-500's pro-migratory and anti-inflammatory actions [6]. The hypothesis: tesamorelin creates a higher-IGF-1 anabolic background; TB-500 provides localized or systemic tissue-remodeling signals. No clinical trial has tested this hypothesis directly.

Evidence Gap Warning

The combination has no RCT, no prospective cohort data, and no published case series in peer-reviewed literature as of this writing. All dosing guidance that follows is synthesized from each agent's individual clinical evidence plus practitioner-reported outcomes in supervised off-label settings. Patients and clinicians should treat every figure below as a starting estimate subject to individual titration, not a validated protocol.

Complete Dosing Protocol

TB-500 Dosing

Clinical practitioners using TB-500 off-label commonly report two phases. A loading phase of 2-2.5 mg administered subcutaneously twice weekly for 4-6 weeks, followed by a maintenance phase of 2-2.5 mg once weekly for the remainder of the cycle.

In rodent wound-healing studies, effective doses scaled to approximately 5-10 mg/kg bodyweight, but human practitioners have settled empirically on flat doses far below that range, citing the absence of toxicity signals rather than dose-response confirmation [1]. Loading-phase total weekly dose therefore runs 4-5 mg; maintenance-phase total weekly dose drops to 2-2.5 mg.

Reconstitution: bacteriostatic water (BAC water), typically 1-2 mL per vial, depending on desired concentration. Store reconstituted peptide refrigerated at 2-8 °C and discard after 28 days.

Tesamorelin Dosing

The FDA-approved regimen for Egrifta SV is 2 mg subcutaneously once daily into the abdomen. In the two key trials that established this dose, 2 mg/day drove the 15.2% mean VAT reduction at 26 weeks cited above [4]. Off-label practitioners sometimes reduce this to 1 mg/day to lower IGF-1 overshoot risk, particularly in patients who are not in the HIV-lipodystrophy indication, but there is no Phase 3 efficacy data at 1 mg/day.

Injection site: Egrifta SV labeling specifies the abdomen; rotate sites to reduce lipohypertrophy. Tesamorelin should not be injected into the same spot used for TB-500 on the same day.

Sample 8-Week Stack Schedule

The table below outlines a starting framework. All doses are subject to physician modification based on IGF-1 and CBC labs.

| Week | TB-500 Dose | TB-500 Frequency | Tesamorelin Dose | Tesamorelin Frequency | |------|-------------|-----------------|------------------|-----------------------| | 1-4 | 2 mg | Twice weekly (Mon/Thu) | 1-2 mg | Daily (AM) | | 5-8 | 2 mg | Once weekly (Mon) | 1-2 mg | Daily (AM) | | 9-12 (optional extension) | 2 mg | Once weekly | 1-2 mg | Daily (AM) |

Timing and Injection Logistics

Tesamorelin is best injected in the morning on an empty stomach or at least 2 hours post-meal. GH secretion follows a circadian rhythm with a natural morning peak, and fasting states enhance GH pulse amplitude. TB-500 timing is less studied; most practitioners separate it from the tesamorelin injection by at least 2-4 hours to avoid confounding any local injection-site reactions, though pharmacokinetic interaction data are absent.

Monitoring and Lab Work

Baseline Labs Before Starting

Patients should have the following before initiating the stack. IGF-1 (serum, morning draw) to establish a pre-treatment baseline. Fasting glucose and HbA1c, because tesamorelin may alter insulin sensitivity in some individuals. A complete metabolic panel, CBC, and, in males over 40, PSA. For patients with a history of pituitary adenoma or any active malignancy, tesamorelin is contraindicated per FDA labeling [3].

On-Cycle Monitoring

Recheck IGF-1 at 4 weeks. Target IGF-1 levels while on tesamorelin are generally considered to be within the upper quartile of the age-adjusted normal reference range. The Endocrine Society's 2011 Clinical Practice Guideline on GH deficiency states that IGF-1 should not chronically exceed 2 standard deviations above the age-matched mean during GH-axis therapy, a principle practitioners carry over to GHRH analogues [7]. If IGF-1 exceeds that threshold, reduce tesamorelin dose to 1 mg/day and recheck in 4 weeks.

Recheck fasting glucose at 8 weeks. A rise of more than 10 mg/dL from baseline warrants dose reduction or discontinuation of tesamorelin and endocrinology consultation.

Why IGF-1 Overshoot Is the Primary Risk

Supraphysiologic IGF-1 has been associated with increased cell proliferation in several in vitro cancer models. A 2004 meta-analysis in Lancet Oncology reported that elevated serum IGF-1 was associated with modestly increased relative risk for prostate, colorectal, and premenopausal breast cancer, though causality was not established [8]. The absolute risk magnitude in a short 8-12 week cycle at physiologic IGF-1 targets is unknown, but this is the primary reason practitioners cap IGF-1 rather than maximizing it.

Safety, Contraindications, and Drug Interactions

Tesamorelin Contraindications

Per Egrifta SV prescribing information, tesamorelin is contraindicated in: disruption of the hypothalamic-pituitary axis (pituitary tumor, trauma, radiation, or active malignancy); known hypersensitivity to tesamorelin or mannitol (an excipient); and pregnancy [3]. The drug is Category X in pregnancy given the potential for fetal GH-axis disruption.

TB-500 Safety Profile

TB-500 lacks FDA approval and has no published Phase 1-3 human safety trials. The absence of reported serious adverse events in practitioner networks does not constitute a clean safety record; it reflects limited structured data collection. Injection-site reactions (erythema, mild swelling) are the most commonly reported adverse events. Theoretical concerns include promotion of angiogenesis in occult tumors, given Tβ4's pro-angiogenic role via VEGF upregulation [1]. Patients with active or recent malignancy should not use TB-500.

Drug Interactions

Tesamorelin may reduce the efficacy of drugs metabolized by CYP450 enzymes whose activity is modulated by GH signaling, including some corticosteroids and sex hormone-binding proteins. The FDA prescribing information specifically notes that tesamorelin may affect cortisol levels, so patients on cortisol replacement therapy require closer monitoring [3]. No specific drug-interaction data exist for TB-500.

Populations Who Should Not Use This Stack

Pregnant or breastfeeding individuals, anyone under 18, patients with active malignancy, patients with active retinopathy (GH elevation can worsen diabetic retinopathy), and patients with uncontrolled diabetes (fasting glucose above 200 mg/dL or HbA1c above 9%) should not start this combination.

Evidence Summary and Grading

| Component | Highest Evidence Level | Key Finding | |-----------|----------------------|-------------| | Tesamorelin for VAT reduction | Phase 3 RCT (N=816) | 15.2% VAT reduction vs. 5.0% placebo at 26 weeks [4] | | Tesamorelin IGF-1 effect | Phase 3 RCT | +114 mcg/L IGF-1 from baseline [4] | | TB-500 wound healing | Animal (rodent) | Accelerated corneal and myocardial repair [1][2] | | TB-500 + tesamorelin combined | None (no published trial) | Mechanism-based hypothesis only |

The Endocrine Society's position on GHRH analogues states: "Tesamorelin should be prescribed only when a clear clinical indication exists and when IGF-1 monitoring is feasible" [7]. Practitioners applying this stack off-label carry the responsibility of approximating those monitoring standards.

Who Is This Stack Best Suited For?

Clinically, the combination has the most theoretical basis in three patient profiles.

Adults in a supervised peptide-assisted recovery program following orthopedic surgery or tendon repair, where TB-500's tissue-remodeling mechanism is most directly relevant and tesamorelin's IGF-1 elevation may support muscle preservation during reduced activity. HIV-positive adults already prescribed Egrifta for lipodystrophy who are also working with a sports-medicine physician on musculoskeletal recovery. And body-composition-focused patients under endocrinology supervision where an elevated IGF-1 target has been established based on a documented low baseline and a clear anabolic goal.

Outside these profiles, the benefit-to-monitoring-burden ratio is less clear, and either agent alone may be more appropriate.

Sourcing, Compounding, and Legal Considerations

Egrifta SV is an FDA-approved pharmaceutical available through licensed pharmacies with a valid prescription. TB-500 is not approved by the FDA for any human use. It is sold as a research chemical by third-party peptide suppliers, and product purity varies substantially. A 2018 study analyzing commercial peptide products found that 30% of samples tested did not match their labeled amino acid sequence or concentration [9]. If a clinician chooses to include TB-500 in a supervised protocol, sourcing from a compounding pharmacy operating under 503B outsourcing facility standards provides greater quality assurance than consumer research-chemical vendors, though 503B compounding of TB-500 occupies regulatory grey territory.

Patients in competitive sports governed by the World Anti-Doping Agency (WADA) should note that both tesamorelin (as a GHRH analogue) and TB-500 (as a peptide hormone or growth factor) appear on the WADA Prohibited List under Section S2 [10].